Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges

• Published in: Virology (New York, N.Y.) Vol. 353; no. 2; pp. 324 - 332
• Main Authors: Wang, Danher, Hevey, Michael, Juompan, Laure Y., Trubey, Charles M., Raja, Nicholas U., Deitz, Stephen B., Woraratanadharm, Jan, Luo, Min, Yu, Hong, Swain, Benjamin M., Moore, Kevin M., Dong, John Y.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 30.09.2006
• Subjects: 60 APPLIED LIFE SCIENCES; Adenoviridae - genetics; Adenoviridae - metabolism; ADENOVIRUS; Amino Acid Sequence; Animals; ANTIBODIES; Antibodies, Viral - blood; Antigens, Viral - biosynthesis; Antigens, Viral - genetics; cAdVax; Cell Line; Cercopithecus aethiops; Challenge; Ci67; Dose-Response Relationship, Immunologic; Ebola Vaccines - administration & dosage; Ebola Vaccines - genetics; Ebola virus; FEVER; Filovirus; Genetic Therapy - methods; Genetic Vectors - metabolism; Glycoprotein; GLYCOPROTEINS; GUINEA PIGS; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Marburg virus; Marburg Virus Disease - blood; Marburg Virus Disease - immunology; Marburg Virus Disease - prevention & control; Marburgvirus - immunology; MICE; Molecular Sequence Data; MORTALITY; Musoke; Ravn; Recombinant Proteins - biosynthesis; Recombinant Proteins - genetics; Sequence Alignment; Vaccination; Vaccine; VACCINES; Vaccines, Synthetic - administration & dosage; VIRAL DISEASES; Viral Envelope Proteins - biosynthesis; Viral Envelope Proteins - genetics; Viral Fusion Proteins - biosynthesis; Viral Fusion Proteins - genetics; Ravn; Marburg virus; cAdVax; Musoke; Glycoprotein; Ci67; Vaccine; Challenge
• ISSN: 0042-6822; 1096-0341
• DOI: 10.1016/j.virol.2006.05.033

The Marburg virus (MARV), an African filovirus closely related to the Ebola virus, causes a deadly hemorrhagic fever in humans, with up to 90% mortality. Currently, treatment of disease is only supportive, and no vaccines are available to prevent spread of MARV infections. In order to address this need, we have developed and characterized a novel recombinant vaccine that utilizes a single complex adenovirus-vectored vaccine (cAdVax) to overexpress a MARV glycoprotein (GP) fusion protein derived from the Musoke and Ci67 strains of MARV. Vaccination with the cAdVaxM(fus) vaccine led to efficient production of MARV-specific antibodies in both mice and guinea pigs. Significantly, guinea pigs vaccinated with at least 5 × 10 7 pfu of cAdVaxM(fus) vaccine were 100% protected against lethal challenges by the Musoke, Ci67 and Ravn strains of MARV, making it a vaccine with trivalent protective efficacy. Therefore, the cAdVaxM(fus) vaccine serves as a promising vaccine candidate to prevent and contain multi-strain infections by MARV.